E-LIB Suche - Ergebnisse für: Polk, Anne

1

Checkpoint inhibitors in breast cancer – Current status:

Polk, Anne ; Svane, Inge-Marie ; Andersson, Michael.
Cancer Treatment Reviews. 63 (2018) - p. 122-134 , 2018

2

Efficacy and safety of regorafenib in the treatment of meta..:

Røed Skårderud, Maria ; Polk, Anne ; Kjeldgaard Vistisen, Kirsten..
Cancer Treatment Reviews. 62 (2018) - p. 61-73 , 2018

Link: https://doi.org/10.1016/..

3

Specific CDK4/6 inhibition in breast cancer: a systematic r..:

Polk, Anne ; Kolmos, Ida Lykke ; Kümler, Iben.
ESMO Open. 1 (2016) 6 - p. e000093 , 2016

Link: https://doi.org/10.1136/..

4

Incidence and risk factors for capecitabine-induced symptom..:

Polk, Anne ; Shahmarvand, Nahid ; Vistisen, Kirsten...
BMJ Open. 6 (2016) 10 - p. e012798 , 2016

Link: https://doi.org/10.1136/..

5

A systematic review of the pathophysiology of 5-fluorouraci..:

Polk, Anne ; Vistisen, Kirsten ; Vaage-Nilsen, Merete.
BMC Pharmacology and Toxicology. 15 (2014) 1 - p. , 2014

Link: https://doi.org/10.1186/..

6

Cardiotoxicity in cancer patients treated with 5-fluorourac..:

Polk, Anne ; Vaage-Nilsen, Merete ; Vistisen, Kirsten.
Cancer Treatment Reviews. 39 (2013) 8 - p. 974-984 , 2013

Link: https://doi.org/10.1016/..

7

Specific CDK4/6 inhibition in breast cancer: a systematic r..:

Polk, Anne ; Kolmos, Ida Lykke ; Kümler, Iben.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5419212/. , 2017

Link: http://www.ncbi.nlm.nih...

8

Incidence and risk factors for capecitabine-induced symptom..:

Polk, Anne ; Shahmarvand, Nahid ; Vistisen, Kirsten...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5073470/. , 2016

Link: http://www.ncbi.nlm.nih...

9

Patient-reported outcome and risk of revision after shoulde..:

Rasmussen, Jeppe V ; Polk, Anne ; Brorson, Stig..
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3967251. , 2014

Link: http://www.ncbi.nlm.nih...

10

Reliability of patient-reported functional outcome in a joi..:

Polk, Anne ; Rasmussen, Jeppe V ; Brorson, Stig.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3584596. , 2013

Link: http://www.ncbi.nlm.nih...

11

Clinical Trials of Immune Checkpoint Inhibitors in Hepatoce..:

Dyhl-Polk, Anne ; Mikkelsen, Marta Kramer ; Ladekarl, Morten.
Journal of Clinical Medicine. 10 (2021) 12 - p. 2662 , 2021

Link: https://doi.org/10.3390/..

12

Wnt5a expression and prognosis in stage II–III colon cancer:

Lund, Cecilia Margareta ; Dyhl-Polk, Anne ; Nielsen, Dorte Lisbeth.
Translational Oncology. 14 (2021) 1 - p. 100892 , 2021

Link: https://doi.org/10.1016/..

13

Myocardial Ischemia Induced by 5-Fluorouracil: A Prospectiv..:

Dyhl-Polk, Anne ; Schou, Morten ; Vistisen, Kirsten K....
The Oncologist. 26 (2020) 3 - p. e403-e413 , 2020

Link: https://doi.org/10.1002/..

14

PD-L1 expression in breast cancer: expression in subtypes a..:

Stovgaard, Elisabeth Specht ; Dyhl-Polk, Anne ; Roslind, Anne..
Breast Cancer Research and Treatment. 174 (2019) 3 - p. 571-584 , 2019

Link: https://doi.org/10.1007/..

15

Checkpoint inhibitors in pancreatic cancer:

Henriksen, Andreas ; Dyhl-Polk, Anne ; Chen, Inna.
Cancer Treatment Reviews. 78 (2019) - p. 17-30 , 2019

Link: https://doi.org/10.1016/..